Firm's cholesterol-lowering agent will be reviewed at the next meeting of FDA's Endocrinologic and Metabolic Drugs Advisory Committee, tentatively scheduled for Feb. 19. Merck filed an NDA for lovastatin in November.
You may also be interested in...
The agency sees its personnel compensation and benefits costs decrease for the first time in at least 16 years, while the overall FTE count continues to rise.
X-ray manufacturers and importers submitting Electronic Product Control reports will only need to submit their variance application package once.
Just five weeks before the US election, a Medtech Insight analysis shows medical device companies are spending more on Democrat Joe Biden’s campaign than on Republican Donald Trump’s.